Overview

Data as of November 19, 2019 08:50 pm EST

Press Releases

Summary Toggle Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

November 11, 2019

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH : demonstrated that resmetirom treatment resulted in statistically significant reduction in hepatic fat measured non-invasively (magnetic resonance imaging-proton density
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

November 06, 2019

CONSHOHOCKEN, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: “Madrigal continued to execute its clinical development strategy in non-alcoholic steatohepatitis (NASH) and non-alcoholic
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

August 07, 2019

-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected for the Liver Meeting ® AASLD 2019 in Boston , November 2019 -- CONSHOHOCKEN, Pa. , Aug.

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf